|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Auersperg N, Wong AS, Choi KC, Kang SK and
Leung PC: Ovarian surface epithelium: Biology, endocrinology, and
pathology. Endocr Rev. 22:255–288. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Quinn JJ and Chang HY: Unique features of
long non-coding RNA biogenesis and function. Nat Rev Genet.
17:47–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wahlestedt C: Targeting long non-coding
RNA to therapeutically upregulate gene expression. Nat Rev Drug
Discov. 12:433–446. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Batista PJ and Chang HY: Long noncoding
RNAs: Cellular address codes in development and disease. Cell.
152:1298–1307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schmitt AM and Chang HY: Long noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hosseini ES, Meryet-Figuiere M,
Sabzalipoor H, Kashani HH, Nikzad H and Asemi Z: Dysregulated
expression of long noncoding RNAs in gynecologic cancers. Mol
Cancer. 16:1072017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y,
Chen W, Liu F, Sun W, Li XF, et al: Exosome-transmitted lncARSR
promotes sunitinib resistance in renal cancer by acting as a
competing endogenous RNA. Cancer Cell. 29:653–668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang FT, Chen WY, Gu ZQ, Zhuang YY, Li
CQ, Wang LY, Peng JF, Zhu Z, Luo X, Li YH, et al: The novel long
intergenic noncoding RNA UCC promotes colorectal cancer progression
by sponging miR-143. Cell Death Dis. 8:e27782017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ji P, Diederichs S, Wang W, Böing S,
Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et
al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tian X and Xu G: Clinical value of lncRNA
MALAT1 as a prognostic marker in human cancer: Systematic review
and meta-analysis. BMJ Open. 5:e0086532015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Nakajima K, Tabatabai ZL, Ishii N and Dahiya R: Long noncoding RNA
MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and
interacts with miR-205. Cancer Res. 75:1322–1331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY,
Zhang F, Wu LM, Chen LM and Zheng SS: Long non-coding RNA MALAT-1
overexpression predicts tumor recurrence of hepatocellular
carcinoma after liver transplantation. Med Oncol. 29:1810–1816.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F
and Liu Y: TGF-β-induced upregulation of malat1 promotes bladder
cancer metastasis by associating with suz12. Clin Cancer Res.
20:1531–1541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu JH, Chen G, Dang YW, Li CJ and Luo DZ:
Expression and prognostic significance of lncRNA MALAT1 in
pancreatic cancer tissues. Asian Pac J Cancer Prev. 15:2971–2977.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Okugawa Y, Toiyama Y, Hur K, Toden S,
Saigusa S, Tanaka K, Inoue Y, Mohri Y, Kusunoki M, Boland CR, et
al: Metastasis-associated long non-coding RNA drives gastric cancer
development and promotes peritoneal metastasis. Carcinogenesis.
35:2731–2739. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng HT, Shi DB, Wang YW, Li XX, Xu Y,
Tripathi P, Gu WL, Cai GX and Cai SJ: High expression of lncRNA
MALAT1 suggests a biomarker of poor prognosis in colorectal cancer.
Int J Clin Exp Pathol. 7:3174–3181. 2014.PubMed/NCBI
|
|
23
|
Shen L, Chen L, Wang Y, Jiang X, Xia H and
Zhuang Z: Long noncoding RNA MALAT1 promotes brain metastasis by
inducing epithelial-mesenchymal transition in lung cancer. J
Neurooncol. 121:101–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jadaliha M, Zong X, Malakar P, Ray T,
Singh DK, Freier SM, Jensen T, Prasanth SG, Karni R, Ray PS, et al:
Functional and prognostic significance of long non-coding RNA
MALAT1 as a metastasis driver in ER negative lymph node negative
breast cancer. Oncotarget. 7:40418–40436. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Q, Su Y, He X, Zhao W, Wu C, Zhang W,
Si X, Dong B, Zhao L, Gao Y, et al: Plasma long non-coding RNA
MALAT1 is associated with distant metastasis in patients with
epithelial ovarian cancer. Oncol Lett. 12:1361–1366. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin Y, Feng SJ, Qiu S, Shao N and Zheng
JH: LncRNA MALAT1 promotes proliferation and metastasis in
epithelial ovarian cancer via the PI3K-AKT pathway. Eur Rev Med
Pharmacol Sci. 21:3176–3184. 2017.PubMed/NCBI
|
|
27
|
Gyorffy B, Lánczky A and Szállási Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dweep H and Gretz N: miRWalk2.0: A
comprehensive atlas of microRNA-target interactions. Nat Methods.
12:6972015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bayoumi AS, Sayed A, Broskova Z, Teoh JP,
Wilson J, Su H, Tang YL and Kim IM: Crosstalk between long
noncoding RNAs and microRNAs in health and disease. Int J Mol Sci.
17:3562016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou D, Zhang L, Sun W, Guan W, Lin Q, Ren
W, Zhang J and Xu G: Cytidine monophosphate kinase is inhibited by
the TGF-β signalling pathway through the upregulation of
miR-130b-3p in human epithelial ovarian cancer. Cell Signal.
35:197–207. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miao Y, Fan R, Chen L and Qian H: Clinical
significance of long non-coding RNA MALAT1 expression in tissue and
serum of breast cancer. Ann Clin Lab Sci. 46:418–424.
2016.PubMed/NCBI
|
|
32
|
Li C, Cui Y, Liu LF, Ren WB, Li QQ, Zhou
X, Li YL, Li Y, Bai XY and Zu XB: High Expression of Long Noncoding
RNA MALAT1 indicates a poor prognosis and promotes clinical
progression and metastasis in bladder cancer. Clin Genitourin
Cancer. 15:570–576. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pang EJ, Yang R, Fu XB and Liu YF:
Overexpression of long non-coding RNA MALAT1 is correlated with
clinical progression and unfavorable prognosis in pancreatic
cancer. Tumour Biol. 36:2403–2407. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu L, Wang X and Guo Y: Long non-coding
RNA MALAT1 is upregulated and involved in cell proliferation,
migration and apoptosis in ovarian cancer. Exp Ther Med.
13:3055–3060. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zou A, Liu R and Wu X: Long non-coding RNA
MALAT1 is up-regulated in ovarian cancer tissue and promotes
SK-OV-3 cell proliferation and invasion. Neoplasma. 63:865–872.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gutschner T, Hämmerle M and Diederichs S:
MALAT1 - A paradigm for long noncoding RNA function in cancer. J
Mol Med. 91:791–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yoshimoto R, Mayeda A, Yoshida M and
Nakagawa S: MALAT1 long non-coding RNA in cancer. Biochim Biophys
Acta. 1859:192–199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Thomson DW and Dinger ME: Endogenous
microRNA sponges: Evidence and controversy. Nat Rev Genet.
17:272–283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiao H, Tang K, Liu P, Chen K, Hu J, Zeng
J, Xiao W, Yu G, Yao W, Zhou H, et al: LncRNA MALAT1 functions as a
competing endogenous RNA to regulate ZEB2 expression by sponging
miR-200s in clear cell kidney carcinoma. Oncotarget. 6:38005–38015.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang SH, Zhang WJ, Wu XC, Zhang MD, Weng
MZ, Zhou D, Wang JD and Quan ZW: Long non-coding RNA Malat1
promotes gallbladder cancer development by acting as a molecular
sponge to regulate miR-206. Oncotarget. 7:37857–37867.
2016.PubMed/NCBI
|
|
42
|
Blahna MT and Hata A: Regulation of miRNA
biogenesis as an integrated component of growth factor signaling.
Curr Opin Cell Biol. 25:233–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Desvignes T, Batzel P, Berezikov E,
Eilbeck K, Eppig JT, McAndrews MS, Singer A and Postlethwait JH:
miRNA nomenclature: A view incorporating genetic origins,
biosynthetic pathways, and sequence variants. Trends Genet.
31:613–626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li D, Hu J, Song H, Xu H, Wu C, Zhao B,
Xie D, Wu T, Zhao J and Fang L: miR-143-3p targeting LIM domain
kinase 1 suppresses the progression of triple-negative breast
cancer cells. Am J Transl Res. 9:2276–2285. 2017.PubMed/NCBI
|
|
45
|
He Z, Yi J, Liu X, Chen J, Han S, Jin L,
Chen L and Song H: MiR-143-3p functions as a tumor suppressor by
regulating cell proliferation, invasion and epithelial-mesenchymal
transition by targeting QKI-5 in esophageal squamous cell
carcinoma. Mol Cancer. 15:512016. View Article : Google Scholar : PubMed/NCBI
|
